On June 21, 2023, with the tremendous support of all stakeholders, CPHI & PMEC China 2023, hosted by Informa Markets and the China Chamber of Commerce for Import & Export of Medicines & Health Products, co-organized by Sinoexpo Informa Markets, concluded successfully at the Shanghai New International Expo Center. Over the course of three days, this exhibition welcomed more than 59,560 professional visitors who came together to explore, network, and gain insights into the industry's latest technology and development trends. Together, they contributed to making this event a significant milestone in the global pharmaceutical landscape.
In a pivotal period of reinvigorating international engagement and bolstering the global economy, face-to-face presentations and exchanges remain indispensable. CPHI & PMEC China serves as a paramount platform for pharmaceutical companies to elevate their brand presence and unveil new technologies and products to a global audience. It is committed to fostering a premium environment where the global pharmaceutical industry can convene, collaborate, and progress collectively.
Spanning an expansive exhibition area of 200,000 square meters, this year's event brought together 3,360 esteemed domestic and international suppliers, accompanied by a groundbreaking attendance of 59,560 professional visitors. Furthermore, over 8,000 international visitors from 129 countries and regions converged at the exhibition, significantly fostering global trade cooperation within the pharmaceutical industry.
Bolstered by favorable policies such as consistency evaluation and centralized procurement, pharmaceutical companies have progressively augmented their investments in research and development (R&D) and production. This has led to the emergence of new technologies, dosage forms, and processes, with innovation, high-end solutions, and differentiated competition emerging as the focal points of enterprise development.
This year's CPHI & PMEC China showcased over 200 internationally renowned brands hailing from countries and regions such as Switzerland, Italy, Germany, the United States, Japan, and South Korea. Among them were esteemed names like Midas Pharma, PharmSol Group, Pfizer CentreOne, IFF Pharma Solutions, CARBOGEN AMCIS, Merck Chemicals, and Lonza. The event also spotlighted outstanding domestic pharmaceutical industry brands including Acebright, Sinopharm Group, HEC Group, Apeloa, Zhejiang Medicine, Hisunpharm, North China Pharmaceutical, CSPC Pharmaceutical Group, Shanghai Pharma, Qilu Pharmaceutical, Huahai Pharmaceutical, and Northeast Pharm. Together, these entities presented their flagship products and cutting-edge technologies, enriching the industry with a plethora of choices and forward-thinking solutions for innovation and upgrading.
Furthermore, CPHI & PMEC China featured various product areas alongside the International Brands and Ingredients section. Highlights included the Natural Extracts area, offering multifunctional raw materials for healthcare products, food and beverages, and cosmetics. The Finished Dosage Formulation area focused on promoting internationalization and fostering win-win cooperation within the global pharmaceutical industry. The "Going Global" Pioneers congregated in the Bio Pharma area, delving into pharmaceutical R&D policies and exploring the future of biopharmaceutical cooperation and transformation. The Excipients area played a crucial role in advancing formulation dosage forms and ensuring drug quality and safety. Meanwhile, the Contract Services area facilitated discussions between domestic and foreign enterprises to spur differentiation and breakthroughs in new drug development.
In the era of Industry 4.0, the pharmaceutical sector has embraced the advancements of the 4.0 era, with automation, informatization, and intelligentization emerging as pivotal factors driving transformation and upgrading within pharmaceutical enterprises. To spearhead industrial development, PMEC China 2023 has centered its focus on "intelligent manufacturing," convening over a thousand high-quality suppliers from various sectors including Pharma Machinery, Packaging & Drug Delivery, Laboratory Instrument & Equipment, Clean Technology & Environmental Protection, Pharma Logistics, Automation & Informatization, and more in Shanghai. Together, they explore the new future of China's pharmaceutical industry.
This year's PMEC China attracted over 100 overseas exhibitors from Belgium, the Netherlands, Spain, Thailand, Malaysia, India, and other countries, showcasing their advanced developments and cutting-edge products. Within the Pharma Machinery segment, leading domestic and international companies such as Tufflon, Truking, SHINVA, and Körber presented progressive achievements and solutions in the realm of "intelligent manufacturing." These offerings provide pharmaceutical enterprises with boundless opportunities to enhance equipment production efficiency and processes, while also fostering high-end, intelligent, and environmentally sustainable development within the industry.
In alignment with industry trends, the Packaging & Drug Delivery segment featured an array of products catering to applications across biopharmaceuticals, chemicals, Chinese medicine, health products, special medical food, and aesthetic medicine. Globally forward-thinking companies and pioneering products congregated in this area, accelerating innovation in domestic pharmaceutical packaging and drug delivery systems.
Meanwhile, the Laboratory Instrument & Equipment segment remains dedicated to driving innovation in laboratory construction and research and development across pharmaceuticals, chemicals, and biotechnology. By championing the development of intelligent laboratories, this segment showcases cutting-edge applications and solutions that contribute to the industry's advancement.
As a global trade benchmark for the pharmaceutical industry, CPHI & PMEC China has cemented its position as a vital link between Chinese pharmaceutical companies and international clients, owing to its exceptional track record in penetrating global markets. Since its inception, the exhibition has consistently provided Chinese pharmaceutical companies with new opportunities to enter the global market, drawing international clients from around the world each year.
One notable feature of CPHI & PMEC China is the "Hosted Buyer Programme," which was successfully held in 2023 as scheduled. With thirteen years of premium matching experience, the event attracted 73 global buyers and facilitated 173 meetings with suppliers over the course of three days. This initiative plays a pivotal role in assisting pharmaceutical companies in forging effective and efficient partnerships. CPHI & PMEC China aims to cultivate a global partnership network within the pharmaceutical industry and facilitate connections for more pharmaceutical companies.
Additionally, CPHI & PMEC China is dedicated to fostering an R&D ecosystem for pharmaceutical professionals while spearheading international trade connections. Nearly 80 concurrent conferences were convened, featuring over 400 domestic and foreign pharmaceutical regulatory officials, industry experts, and entrepreneurs. These sessions covered a wide array of topics spanning the entire pharmaceutical industry chain. The conferences attracted over a thousand international industry leaders, fostering deeper communication on various fronts such as international pharmaceutical regulations, foreign trade dynamics, industry trends, pharmaceutical R&D, and intelligent manufacturing. This comprehensive approach helps enterprises optimize their strategic layouts, explore investment and trade opportunities, and ultimately contribute to strategic decisions and innovations within the pharmaceutical sector.
Following the success of the recently concluded CPHI & PMEC China, a new Roadshow is set to take place in the city of Guangzhou, Guangdong Province, at the PWTC Expo from September 4th to 6th, 2023. The decision to launch this special roadshow was driven by the significant demand observed from international audiences, particularly in the Guangdong region. Expecting participation from over 200 regional companies, the event has been tailored to cater to international attendees from across Pan Asia, Europe, and the USA. With an anticipated attendance of over 10,000 visitors, the roadshow will span an exhibition space of 10,000sqm, featuring more than 10 onsite conferences.
Looking ahead, CPHI & PMEC China 2024 is poised to continue its mission of building a high-quality global pharmaceutical industry trading platform. Fueled by innovation and R&D, the event will further deepen brand promotion and facilitate the efficient expansion and global connections of companies within the industry.
As the current exhibition comes to a close, it marks the beginning of a new chapter. While the journey continues, the future holds great promise. We eagerly anticipate your participation in CPHI & PMEC China 2024 in Shanghai!
